Medra
Physical AI for hypothesis generation, robotic experiments, and biopharma research workflows.
The Company
Medra is building a Physical AI Scientist that combines scientific reasoning with general-purpose robots that can execute experiments. The company says the system is designed to run a tighter loop between designing, conducting, and interpreting laboratory work.
In December 2025, Medra announced a $52 million Series A led by Human Capital. It named Genentech, Cultivarium, and Addition Therapeutics as early biopharma partners, while the funding announcement did not disclose a valuation.
Why It Matters
Drug discovery is a high-value application for AI, but the bottleneck often remains physical experimental work. Medra is a private-market bet on bringing model-driven workflows directly into laboratory execution.
Valuation History
- Raised $52M · valuation undisclosed→Dec 2025Series ASource ↗
What Changed
Medra announced a $52M Series A led by Human Capital.
THE NEXT COMPANY. A CLEARER PICTURE.
Get the next breakdown.
Independent company research and perspectives on private markets, delivered through The Private Ledger on Substack.